VIARTIS

 

 

 

 

 

PARKINSON'S DISEASE NEWS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9th May 2010 - New research

TOLCAPONE CLINICAL TRIAL RESULTS

CNS Spectrums [2010] 15 (1) : 27-32 (K.Sethi, S.Factor, R.Watts) Complete abstract
                                                                                                                                                                                 C
hanges in the quality of life (QOL) were assessed in people with Parkinson's Disease after thirty days of the use of Tolcapone being added to their existing treatments. Tolcapone, whose brand name is Tasmar, is a COMT inhibitor, which is drug that helps to maintain the levels of dopamine, the substance whose deficiency causes Parkinson's Disease. For more information go to Tolcapone. After thirty days of Tolcapone use the mean PDQ-8 total score (which assesses basic Parkinson's Disease symptoms) improved from 42.1 to 34.8. Nearly 70% of the patients also improved on the CGI-I (the investigator's impression of improvement). Physicians planned to continue the use of Tolcapone beyond the thirty days in 72% of cases, most commonly because of the improvements in motor function and overall general improvement. However, the side effects it caused were not detailed. Tolcapone is the same kind of drug as Entacapone, which is more  commonly used.  Entacapone is sold on its own as Comtan, or in combination with Sinemet as Stalevo. For more current news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

    Back to PARKINSON'S DISEASE 

 

 
2006-2010  Viartis
 
2015-11-09 11:05:27
 
[email protected]